In colorectal cancer, where PD-1 blockade shows minimal efficacy as monotherapy in pMMR/MSS tumours [42], Treg-mediated immune suppression has been proposed as a potential mechanism underlying therapeutic failure and the improved outcomes observed with combined PD-(L)1 and CTLA-4 inhibition [39]. This evidence concerns the gene CTLA4 and colorectal cancer.